Saturday Nov 7 | Posted by: roboblogger
Amgen Announces Overall Survival Results for Vectibix in First-Line Metastatic Colorectal Cancer
Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix administered in combination with FOLFOX as a first-line treatment of metastatic colorectal cancer failed to meet a secondary endpoint of overall survival.
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
Other Recent Biotech Discussions
Search the Biotech Forum:
Search the Biotech Forum:
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| FHA Mortgage Focus Fuels Lend America's Rise (Jan '09) | 38 min | b-52s rule | 289 |
| Vaccine breaks out of the pack | 4 hr | Sheri | 37 |
| MDRNA: Enhancing value for our partners and sh... | 7 hr | JIMMY T | 2 |
| CDC Warns: Holiday Could Bring More Swine Flu | 8 hr | spam | 7 |
| Vioxx risks could have been identified years ea... | 14 hr | Iowagolfer | 1 |
| Merck to fund Vioxx settlement in August (Aug '08) | 22 hr | jman | 6651 |
| CDC warns holiday season may bring more swine flu | Thu | sixten5 | 4 |
Daily Horoscope for November 27
Cancer
You may receive kudos from your superiors or important people in your community and the Moon blends with the Sun to encourage rewards from The Powers That Be. This has the potential to be a wonderful time for you. Look for growth-encouraging opportunities that will pay off in the new year.
